Nanowear/Satio logo

纳米穿戴/萨蒂奥标志

Cutting Edge At-Home MedTech and Digital Health Companies, Satio and Nanowear, to Collaborate on Accelerating Non-invasive Biomarkers, Diagnostics and Drug Delivery, Beyond the Remote Monitoring and Digital Assessment Tools Used Today

前沿的家庭医疗科技和数字健康公司Satio与Nanowear将合作加速非侵入性生物标志物、诊断及药物递送，超越当前使用的远程监控和数字评估工具。

BOSTON

波士顿

and

和

NEW YORK

纽约

,

，

April 14, 2025

2025年4月14日

/PRNewswire/ -- Satio and Nanowear have agreed to partner to advance patient-friendly, home-based diagnostic, and therapeutic care. This collaboration integrates Nanowear's at-home AI-based nanotechnology biomarker diagnostic platform with Satio's at-home blood draw diagnostics and drug delivery systems/patches: combining time synchronous, in vivo and in vitro diagnostics for precision therapeutics and individualized AI-based risk assessment..

/PRNewswire/ -- Satio与Nanowear达成合作，共同推进患者友好的家庭诊断和治疗护理。此次合作将Nanowear基于家庭的AI纳米技术生物标志物诊断平台与Satio的家庭抽血诊断及药物输送系统/贴片相结合：融合时间同步的体内和体外诊断，以实现精准治疗和基于人工智能的个性化风险评估。

Since 2019, patients, healthcare systems, pharmaceutical companies, medtech firms, and direct-to-consumer (DTC) clinical trials have increasingly adopted home-based digital care. However, widespread adoption has been hindered by challenges in accuracy, reliability, cost, workflow integration, and limited access to actionable data and interoperability.

自 2019 年以来，患者、医疗系统、制药公司、医疗技术公司和直接面向消费者 (DTC) 的临床试验越来越多地采用基于家庭的数字护理。然而，准确性、可靠性、成本、工作流程整合方面的挑战，以及对可用数据和互操作性访问的限制，阻碍了其广泛应用。

These barriers have led to frustration and underutilization, highlighting the urgent need for more seamless and effective solutions in remote healthcare..

这些障碍导致了挫败感和资源利用不足，突显了远程医疗中对于更加无缝和有效的解决方案的迫切需求。

Nanowear is transforming home-based cardiometabolic healthcare with end-to-end FDA approved cloth nanotechnology and AI diagnostics, SimpleSense™, delivering a full cardiometabolic assessment and continuous picture of individualized health through the use of an AI digital diagnostic platform, while the patient is in the comfort of their own home.

Nanowear正在通过端到端的FDA批准的布料纳米技术和人工智能诊断工具SimpleSense™，彻底改变基于家庭的心脏代谢健康护理。该技术通过使用人工智能数字诊断平台，在患者舒适地待在家中时，提供全面的心脏代谢评估和个性化的健康持续监测。

The SimpleSense™ platform simultaneously and time synchronously collects 85+ clinically validated cardiopulmonary and hemodynamic biomarkers, replacing first line diagnostic tools such as the continuous blood pressure line, digital stethoscope, multi-channel ECG, hemodynamic, spirometer, actigraphy monitors as well as continuous glucose monitoring (CGM) via a recently announced CGM integration and data .

SimpleSense™ 平台可同时且时间同步地收集 85 种以上经过临床验证的心肺和血液动力学生物标志物，取代一线诊断工具，如连续血压监测线、数字听诊器、多通道心电图、血液动力学监测仪、肺活量计、活动监测仪以及通过最近宣布的 CGM 集成和数据实现的连续血糖监测 (CGM)。

partnership.

伙伴关系。

Satio, which recently had its remotely controlled drug delivery telemedicine episode recognized as the first Advanced Research Development Agency for Health ARPA-H Challenge program to be completed, enables

Satio最近因其远程控制药物输送的远程医疗项目被认可为第一个完成的高级卫生研究与发展局ARPA-H挑战计划，这使得

decentralized

去中心化的

care by transforming workflow with its patch-based adhesive technology to shift care from clinics to the home for blood-based diagnostics and drug delivery procedures.  This partnership allows Satio's decentralization efforts to be accelerated with cutting-edge robust information capture and analytics..

通过其基于贴片的粘附技术转变工作流程，将血液诊断和药物输送程序的护理从诊所转移到家庭。这项合作使Satio的去中心化努力能够通过前沿的稳健信息捕获和分析得到加速。

Nanowear and Satio are exploring multiple collaboration pathways to revolutionize home-based diagnostics and care. One initiative focuses on integrating Satio's SatioDot dry blood spot and SatioDraw whole blood draw in vitro patches with Nanowear's SimpleSense system. This novel combination — merging blood and genotype biomarkers with cardiometabolic physiological data within a single digital app — marks a first-of-its-kind advancement in biopharma, pharmaceutical, medtech, and biotech clinical research, a market valued at approximately .

Nanowear 和 Satio 正在探索多条合作途径，以彻底改变基于家庭的诊断和护理。其中一个项目专注于将 Satio 的 SatioDot 干血斑和 SatioDraw 全血抽取体外贴片与 Nanowear 的 SimpleSense 系统相结合。这种新颖的组合——在一个数字应用程序中整合血液和基因型生物标志物以及心脏代谢生理数据——标志着生物制药、制药、医疗技术和生物技术临床研究领域的首次此类进步，该市场价值约为 。

$55 billion

550亿美元

annually. In a complementary approach, Nanowear's SimpleSense biomarkers would be incorporated into SatioRx's telehealth drug delivery system, enabling dynamic reporting and next-generation home-based care in a

每年。在一种互补的方法中，Nanowear的SimpleSense生物标志物将被整合到SatioRx的远程医疗药物输送系统中，从而实现动态报告和下一代基于家庭的护理。

~$200 billion

约2000亿美元

total addressable market. Additionally, Nanowear and Satio will jointly promote their technologies and combined capabilities to key stakeholders, further accelerating innovation in digital healthcare.

总可寻址市场。此外，Nanowear 和 Satio 将联合向关键利益相关者推广他们的技术和综合能力，进一步加速数字医疗领域的创新。

'We are excited about the opportunities to merge in vitro and in vivo results and to enhance chronic disease, cardiometabolic and cancer drug delivery,' says Namal Nawana, Chairman and Founder of Satio, 'And as I've seen in diagnostics and orthopedics, shifting care away from brick and mortar requires not just disrupting workflow, but ensuring information flow is enhanced.  This partnership will help ensure the patient's ease of mind and the clinician's decision-making are strengthened, not thrown into doubt.'.

“我们对将体外和体内结果相结合的机会感到兴奋，并且增强慢性病、心脑代谢和癌症药物的递送，”Satio董事长兼创始人纳马尔·纳瓦纳表示，“正如我在诊断和骨科领域所见，将护理从传统的实体机构转移出去，不仅需要打破工作流程，还要确保信息流得到增强。此次合作将有助于确保患者安心，并加强临床医生的决策，而不是引发疑虑。”

'Our genes, blood, heart, lungs, vasculature, hemodynamic, and metabolic systems all talk to each other in very specific ways from patient to patient,' says

“我们的基因、血液、心脏、肺、血管系统、血流动力学和代谢系统在患者之间都以非常特定的方式相互交流，”

Venk Varadan

文卡·瓦拉丹

, CEO and Co-founder of Nanowear. 'This collaboration of the technologies that combine these key determinants of human health, result in a first-of-its-kind platform that will truly unlock early diagnosis and precision medicine.'

Nanowear的首席执行官兼联合创始人表示：“结合这些人类健康关键决定因素的技术合作，打造了一个前所未有的平台，将真正实现早期诊断和精准医疗。”

'Precision medicine, individualized risk assessment, early diagnosis, home-based care… these were big buzz words that helped frame the digital health landscape post 2020 pandemic. What's been holding these capabilities back is the inability to time synchronously combine all of the relevant biomarkers that are individual to our unique bodies.

“精准医疗、个体化风险评估、早期诊断、居家护理……这些是2020年疫情后帮助构建数字健康领域的大热词汇。而阻碍这些能力发展的，是我们无法同步整合与我们独特身体相关的所有生物标志物。

When .

当时。

all

全部

of the health determinant biomarkers are available through a single data fire hose, AI precision medicine will make us healthier and save our healthcare system trillions.'

的健康决定因素生物标志物可以通过单一的数据管道获得，人工智能精准医疗将使我们更加健康，并为我们的医疗系统节省数万亿。

Satio products are not yet approved for use in the US or other territories.

Satio 产品尚未获准在美国或其他地区使用。

ABOUT NANOWEAR, INC

关于纳米穿戴公司

Nanowear is a leading healthcare-at-home digital diagnostics company providing a smarter way to collect and analyze cardiometabolic health through real-world evidence. Its nanotechnology sensors coupled with its end-to-end software, mobile, and AI-powered platform is a radical leap forward in clinical research and virtual care, empowering physician decision-making with scored, clinical-grade diagnostics through patented nanotechnology and AI diagnostics ultimately providing early diagnosis and precision medicine.

Nanowear是一家领先的居家医疗数字诊断公司，通过真实世界证据提供更智能的心脏代谢健康数据收集与分析方式。其纳米技术传感器结合端到端的软件、移动端和人工智能驱动平台，在临床研究和虚拟护理领域实现了革命性飞跃，通过专利纳米技术和人工智能诊断为医生决策赋能，提供评分化、临床级别的诊断，最终实现早期诊断和精准医疗。

To learn more, visit .

要了解更多信息，请访问 。

www.nanowearinc.com

www.nanowearinc.com

ABOUT SATIO, INC

关于SATIO公司

Satio is on a mission to decentralize healthcare by transforming workflow – in diagnostics, medicine delivery, and streamlined patient-provider interactions through deployment of connecting technologies and biometrics.  Through this mission, Satio endeavors to make people healthier while decreasing costs and burdens.

Satio致力于通过转变工作流程来去中心化医疗保健——在诊断、药品配送和通过连接技术和生物识别技术简化医患互动方面。通过这一使命，Satio努力让人们更健康，同时降低成本和负担。

Satio is a privately held medical device company focused on point-of-need adhesive patches developing three different platforms. The first, SatioRx, is a reusable drug delivery platform to enable stable and controlled delivery of liquid medicines intradermally or subcutaneously. The second platform is dry blood spot (SatioDot.

Satio是一家私营的医疗设备公司，专注于开发点对点需求的粘性贴片，共开发三个不同的平台。第一个平台是SatioRx，是一个可重复使用的药物输送平台，能够稳定和控制液体药物的真皮或皮下输送。第二个平台是干血点（SatioDot）。

TM

商标

) and whole blood sampling (SatioDraw

）和全血采样（SatioDraw

TM

商标

) patches that facilitate home-use for a wide variety of lab-based and genomic testing. Those two diagnostics products are in late-stage clinical development. The third, SatioDx

）这些贴片方便了基于实验室和基因组测试的广泛家庭使用。这两个诊断产品处于临床开发的后期阶段。第三个，SatioDx

TM

商标

, is a consumer-based patch for direct testing, including results on-board the device in real time.

，是一个基于消费者的直接测试补丁，包括设备上的实时结果。

Satio, Inc.

萨蒂奥公司

,

，

'The SatioDx project has been fully funded with Federal funds from The Advanced Research Projects Agency for Health (ARPA-H), Department of Health and Human Services, under Contract No. 75N91023C00059 September 29, 2023.'

“SatioDx 项目已获得来自美国卫生与公众服务部高级研究计划局（ARPA-H）的联邦资金全额资助，合同编号为 75N91023C00059，日期为 2023 年 9 月 29 日。”

SOURCE Satio

源萨蒂奥

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用